Press Release: Hamilton Thorne Reports Financial and Operational Results for the Quarter-Ended September 30, 2021
Press Release: Hamilton Thorne Reports Financial and Operational Results for the Quarter-Ended September 30, 2021
Hamilton Thorne Reports Financial and Operational Results for the Quarter-Ended September 30, 2021
Hamilton Thorne報告截至2021年9月30日的季度的財務和運營業績
Revenues up 30%; Adjusted EBITDA up 22% for the quarter;
收入增長30%；調整後的EBITDA本季度增長22%；
Revenues up 33% and Adjusted EBITDA up 67% for the nine-month period
前9個月收入增長33%，調整後EBITDA增長67%
BEVERLY, Mass. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported unaudited financial and operational results for the quarter and nine months ended September 30, 2021.
馬薩諸塞州貝弗利多倫多，2021年11月22日(環球社)--為輔助生殖技術(ART)、研究和細胞生物學市場提供精密儀器、耗材、軟件和服務的領先供應商Hamilton Thorne Ltd.(多倫多證券交易所股票代碼：HTL)今天公佈了截至2021年9月30日的季度和9個月未經審計的財務和運營業績。
Highlights
亮點
-- Sales increased 30% year over year to $12.7 million for the quarter and
increased 33% to $36.7 million for the nine-month period; constant
currency increase of 24% for the quarter and 28% for the nine-month
period
-- Gross profit increased 23% to $6.0 million for the quarter and 31% to
$18.3 million for the nine-month period
-- Net income was $249 thousand for the quarter and $1.6 million for the
nine-month period, versus $459 thousand and $10 thousand in the prior
year periods
-- Adjusted EBITDA increased 22% to $2.0 million for the quarter and 67% to
$6.8 million for the nine-month period
-- Organic growth in USD was 16% for the quarter, 11% in constant currency;
organic growth was 28% for the nine-month period, 21% in constant
currency
-- Cash generated from operations was $549 thousand for the quarter, and
$3.8 million for the nine-month period; total cash on hand at September
30, 2021 was $18.0 million
-本季度銷售額同比增長30%，達到1270萬美元
9個月內增長33%，達到3670萬美元；不變
本季度貨幣增長24%，9個月增長28%
期間
-毛利潤增長23%，達到600萬美元，增長31%，達到
前九個月1,830萬美元
-本季度淨收入為24.9萬美元，本季度淨收入為160萬美元
9個月，而前一季度為45萬9千美元和10000美元
年份週期
-調整後的EBITDA增長22%，達到200萬美元，增長67%，達到
前九個月$680萬
--本季度以美元計算的有機增長為16%，按不變貨幣計算為11%；
前9個月的有機增長率為28%，恆定增長率為21%
貨幣
-本季度運營產生的現金為54.9萬美元，以及
前九個月380萬美元；截至9月份手頭現金總額
302021年是1800萬美元
"Our third quarter highlighted the continued strength of our business," stated David Wolf, President and Chief Executive Officer. "Sales of $12.7 million reflects a record quarter and were up 30% versus the third quarter of 2020. Sales of $36.7 million for the nine months increased 33% over the prior year. Looking at our growth excluding the impact of Covid-19 and acquisitions, we grew sales organically at compounded annual growth of approximately 16% for the third quarter of 2021 versus the pre-pandemic third quarter of 2019."
總裁兼首席執行官大衞·沃爾夫説：“我們的第三季度突出了我們業務的持續實力。“銷售額達到創紀錄的1,270萬美元，比2020年第三季度增長了30%。前九個月銷售額為3,670萬美元，同比增長33%。剔除新冠肺炎和收購的影響後，我們在2021年第三季度的銷售額實現了有機增長，與疫情爆發前的第三季度相比，複合年增長率約為16%。”
Three- and Nine-Month Periods Ending September 30
Three Months Nine Months
Statements of
Operations: 2021 2020 2021 2020
------------- ---------- ----------- -----------
Sales $12,685,066 $9,793,572 $36,731,264 $27,521,207
Gross profit 6,020,724 4,909,228 18,291,833 13,921,632
Operating
expenses 5,553,997 4,199,819 15,760,895 12,516,473
Net income
(loss) 249,319 459,289 1,597,613 10,348
Adjusted EBITDA 2,034,466 1,668,075 6,801,110 4,068,950
Basic earnings per
share $0.00 $0.00 $0.01 $0.00
Diluted earnings per
share $0.00 $0.00 $0.01 $0.00
Statements of
Financial Position
as at: Sep. 30, 21 Dec. 31, 20
----------- -----------
Cash $18,047,045 $21,828,443
Working capital 22,634,365 22,076,872
Total assets 75,146,516 69,808,718
Non-current
liabilities 10,347,127 7,008,568
Shareholders'
equity 54,304,600 51,065,925
截至9月30日的三個月和九個月期間
三個月九個月
的聲明
運營：2021年2020年2021年2020年
------------- ---------- ----------- -----------
銷售額12,685,066美元9,793,572美元36,731,264美元27,521,207美元
毛利6,020,724 4,909,228 18,291,833 13,921,632
運營中
開支5,553,997 4,199,819 15,760,895 12,516,473
淨收入
(損失)249,319 459,289 1,597,613 10,348
調整後的EBITDA 2,034,466 1,668,075 6,801,110 4,068,950
人均基本收入
股票$0.00$0.00$0.01$0.00
稀釋後每股收益
股票$0.00$0.00$0.01$0.00
的聲明
財務狀況
截止日期：20年9月30日21月31日
----------- -----------
現金$18,047,045$21,828,443
營運資金22,634,365 22,076,872
總資產75,146,516 69,808,718
非電流
負債10,347,127 7,008,568
股東的
股本54,304,600 51,065,925
All amounts are in US dollars, unless specified otherwise, and results, with the exception of Adjusted EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS").
除另有説明外，所有金額均以美元計算，除經調整EBITDA外，業績均按國際財務報告準則(“IFRS”)表示。
Mr. Wolf continued, "Sales of consumables and services, which closely correlate to increased activity at our customer sites, augmented by our market share gains, were up over 30%, while equipment sales, reflecting more normalized demand augmented by the IVFtech acquisition, were up 28% for the quarter. Gross profit margins decreased to 47.5% for the quarter and to 49.8% for the nine months ended September 30, 2021, versus 50.1% and 50.6% for the comparable periods in 2020 primarily due to product and channel mix and increased costs of materials and shipping due to supply chain issues."
沃爾夫先生繼續説：“消費品和服務的銷售額增長了30%以上，這與我們客户活動的增加密切相關，我們的市場份額也有所增加，而本季度設備銷售額增長了28%，反映出收購IVFtech後需求更加正常化。本季度毛利率降至47.5%，截至2021年9月30日的9個月毛利率降至49.8%，而2020年同期分別為50.1%和50.6%，主要原因是產品和渠道組合以及材料和服務成本的增加。在截至2021年9月30日的9個月裏，毛利率分別降至47.5%和49.8%，而2020年同期的毛利率分別為50.1%和50.6%，這主要是由於產品和渠道組合以及材料和服務成本的增加。
The Company continues to be active with its acquisition program. In July, the Company acquired IVFtech ApS, which manufactures laminar flow workstations for controlling temperature, air flow, and air quality in ART and laboratory markets worldwide, as well as flatbed incubators and a number of accessories and related products. The Company also acquired IVFtech's affiliated direct sales business, K4 Technology ApS. This acquisition adds a number of high-quality product lines with significant growth potential to our product portfolio, and establish a direct sales presence for the entire Hamilton Thorne product range in the Nordics region of Denmark, Sweden, Norway, Finland and Iceland.
該公司繼續積極執行其收購計劃。今年7月，該公司收購了IVFtech APS，該公司生產層流工作站，用於控制全球藝術和實驗室市場的温度、氣流和空氣質量，以及平板孵化器和一些配件及相關產品。該公司還收購了IVFtech的附屬直銷業務K4 Technology APS。此次收購為我們的產品組合增加了許多具有顯著增長潛力的高質量產品系列，並在丹麥、瑞典、挪威、芬蘭和冰島的北歐地區建立了整個Hamilton Thorne產品系列的直銷業務。
The Company has an active pipeline and is working on multiple opportunities. With approximately $18 million in cash and $12 million of available lines of credit, Hamilton Thorne is well positioned to execute on additional acquisition opportunities.
該公司有一個活躍的渠道，並正在努力尋找多個機會。漢密爾頓·索恩擁有大約1800萬美元的現金和1200萬美元的可用信貸額度，能夠很好地把握更多的收購機會。
The Company reported that operating expenses were generally in line with expectations, with increased costs associated with maintaining investments in R&D and sales and support personnel, variable costs of sales returning to historical levels, and acquisition expenses post-transactions.
該公司報告説，運營費用總體上符合預期，與保持對研發、銷售和支持人員的投資相關的成本增加，銷售的可變成本恢復到歷史水平，以及交易後的收購費用。
OUTLOOK
展望
Mr. Wolf added, "Our outlook for the balance of the year is positive with expected normalized sales growth in the fourth quarter which should continue for the foreseeable future. While supply chain issues have created new challenges, we believe that they are affecting all market participants and we have demonstrated our ability to navigate product shortages and extended lead times without a material impact on sales. We are planning across the board price increases in early 2022 that should address the margin impacts we had in Q3. We do repeat our caution that the resurgence of Covid-19 cases in certain parts of the world based on new variants and the supply chain issues we have discussed could impact on sales and profitability for a period of time that is difficult to predict."
沃爾夫先生補充説：“我們對今年剩餘時間的展望是積極的，預計第四季度銷售增長將正常化，這種增長在可預見的未來應該會持續下去。雖然供應鏈問題帶來了新的挑戰，但我們相信它們正在影響所有的市場參與者，我們已經證明瞭我們有能力在不對銷售造成實質性影響的情況下解決產品短缺和延長交貨期的問題。我們計劃在2022年初全面提價，這應該會解決我們在第三季度對利潤率的影響。我們確實重申我們的警告，即基於新變種和我們討論過的供應鏈問題的新冠肺炎案例在世界某些地區死灰復燃，可能會在一段難以預測的時間內影響銷售和盈利能力。
Conference Call
電話會議
The Company will hold a conference call on Monday, November 22, 2021, at 11:00 a.m. EST to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 5078809. The Company's updated investor presentation and a recording of the call will be available on Hamilton Thorne's website shortly after the call.
公司將於2021年11月22日(星期一)上午11點召開電話會議。EST回顧了結果的亮點。歡迎所有感興趣的各方通過在北美撥打免費電話1-855-223-7309或在其他地點撥打647-788-4929參加電話會議，並請求會議ID 5078809。該公司最新的投資者介紹和電話會議的錄音將在電話會議結束後不久在漢密爾頓·索恩的網站上公佈。
Financial statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.
這些時期的財務報表和隨附的管理層討論和分析可在www.sedar.com和Hamilton Thorne網站上查閲。
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
關於漢密爾頓·索恩有限公司(www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, and Tek-Event brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Hamilton Thorne是一家全球領先的精密儀器、耗材、軟件和服務供應商，致力於降低成本、提高生產率、改善結果，並在輔助生殖技術(ART)、研究和細胞生物學市場取得突破。漢密爾頓·索恩公司通過其在世界各地不斷壯大的銷售隊伍和分銷商，以漢密爾頓·索恩、吉美美、Planer、IVFtech、Embryotech實驗室和Tek-Event等品牌營銷其產品和服務。漢密爾頓·索恩的客户羣包括生育診所、大學研究中心、動物繁育設施、製藥公司、生物技術公司以及其他商業和學術研究機構。
Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
The Company has included Adjusted EBITDA, Organic Growth, and Constant Currency as non-IFRS measures, which are used by management as measures of financial performance. See section entitled "Use of Non-IFRS Measures" and "Results of Operations" in the Company's Management Discussion and Analysis for the periods covered for further information and a reconciliation of Adjusted EBITDA to Net Income.
該公司已將調整後的EBITDA、有機增長和不變貨幣作為非IFRS衡量標準，管理層將其用作財務業績衡量標準。有關更多信息和調整後EBITDA與淨收入的核對，請參閲公司管理層討論和分析中題為“非IFRS措施的使用”和“經營結果”的章節。
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.
本新聞稿中的某些信息可能包含前瞻性陳述。這些信息基於當前的預期，這些預期受到難以預測的重大風險和不確定性的影響。實際結果可能與任何前瞻性陳述中建議的結果大不相同。公司沒有義務更新前瞻性陳述，也沒有義務更新實際結果可能與前瞻性陳述中反映的結果不同的原因，除非和直到適用於公司的證券法要求。識別風險和不確定性的更多信息包含在該公司向加拿大證券監管機構提交的文件中，這些文件可在www.sedar.com上查閲。
For more information, please contact:
如需更多信息，請聯繫：
David Wolf, President & Michael Bruns, CFO Glen Akselrod Bristol
CEO Hamilton Thorne Ltd. Hamilton Thorne Ltd. Investor Relations
978-921-2050 978-921-2050 905-326-1888
ir@hamiltonthorne.ltd ir@hamiltonthorne.ltd glen@bristolir.com
大衞·沃爾夫，總裁兼邁克爾·布朗斯，首席財務官格倫·阿克塞爾羅德·布裏斯托爾
首席執行官漢密爾頓·索恩有限公司漢密爾頓·索恩有限公司投資者關係
978-921-2050 978-921-2050 905-326-1888
電子郵箱：ir@hamiltonthorne.ltd ir@hamiltonthorne.ltd Glen@bristolir.com
譯文內容由第三人軟體翻譯。